Evidence map›Paper›PMID 39975272›Full record

ArticlebioRxiv : the preprint server for biology2025

A Comparative Evaluation of Computational Models for RNA modification detection using Nanopore sequencing with RNA004 Chemistry.

Yongji Zou, Mian Umair Ahsan, Joe Chan, Wen Meng, Shou-Jiang Gao, Yufei Huang, Kai Wang

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yongji ZouCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0009-0008-4380-4670
Mian Umair AhsanCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0003-4725-2451
Joe ChanCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Wen MengCancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Shou-Jiang GaoCancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yufei HuangCancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kai WangCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0002-5585-982X

Funding

Novel bioinformatics methods to detect DNA and RNA modifications using Nanopore long-read sequencingR01HG013359 · NHGRI · CHILDREN'S HOSP OF PHILADELPHIA · PI Kai Wang · 2023 to 2026
$2.8M
m6A-suite: an informatics pipeline and resource for elucidating roles of m6A epitranscriptome in cancerU01CA279618 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HUANG, YUFEI · 2023 to 2025
$1.8M
NCI NIH HHS U01 CA279618NHGRI NIH HHS R01 HG013359
6 · The paper itself

Abstract

Direct RNA sequencing from Oxford Nanopore Technologies (ONT) has become a valuable method for studying RNA modifications such as N6-methyladenosine (m6A), pseudouridine (ψ), and 5-methylcytosine (m5C). Recent advancements in the RNA004 chemistry substantially reduce sequencing errors compared to previous chemistries (e.g., RNA002), thereby promising enhanced accuracy for epitranscriptomic analysis. In this study, we benchmark the performance of two state-of-the-art RNA modification detection models capable of handling RNA004 data - ONT's Dorado and m6Anet - using two wild-type (WT) cell lines, HEK293T and HeLa, with respective ground truths from GLORI and eTAM-seq, and their paired in vitro transcribed (IVT) RNA as negative controls. We found that under default settings and considering sites with ≥10% modification ratio and ≥10X coverage, Dorado has higher recall (~0.92) than m6Anet (~0.51) for m6A detection. Among the overlapping methylated sites between ground truth and computational predictions, there are high correlations of site-specific m6A modification stoichiometry, with correlation coefficient of ~0.89 for Dorado-truth comparison and ~0.72 for m6Anet-truth comparison. However, combined assessment of WT and IVT datasets show that while the per-site false positive rate (FPR) can be lower (~8% for Dorado and ~33% for m6Anet), both computational tools can have high per-site false discovery rate (FDR) of m6A (~40% for Dorado and ~80% for m6Anet) due to the low prevalence of m6A in transcriptome, with a similar trend observed for pseudouridine (~95% FDR for Dorado). Additional motif analysis reveals that both Dorado and m6Anet exhibit high heterogeneity of false positive calls across sequence contexts, suggesting that sequence contexts help determine accuracy of specific modification calls. There is also a substantial overlap of false positive calls between the two IVT samples, suggesting a post-filtering strategy to improve modification calling by compiling a set of low-confidence sites with a probabilistic model from several IVT samples across diverse cells/tissues. Our analysis highlights key strengths and limitations of the current generation of m6A detection algorithms and offers insights into optimizing thresholds and interpretability. The IVT datasets generated by the RNA004 chemistry provides a publicly available benchmark resource for further development and refinement of computational methods.

Identifiers

PMID39975272
PMCPMC11838592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.